Last updated: 24 June 2024 at 4:24pm EST

Sandra Horning Net Worth




The estimated Net Worth of Sandra Horning is at least 111 千$ dollars as of 28 April 2023. Sandra Horning owns over 670 units of Gilead Sciences stock worth over 111,131$ and over the last 5 years he sold GILD stock worth over 0$. In addition, he makes 0$ as Independent Director at Gilead Sciences.

Sandra Horning GILD stock SEC Form 4 insiders trading

Sandra has made over 4 trades of the Gilead Sciences stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 670 units of GILD stock worth 54,230$ on 28 April 2023.

The largest trade he's ever made was exercising 1,112 units of Gilead Sciences stock on 3 May 2022 worth over 90,005$. On average, Sandra trades about 148 units every 39 days since 2020. As of 28 April 2023 he still owns at least 1,373 units of Gilead Sciences stock.

You can see the complete history of Sandra Horning stock trades at the bottom of the page.





Sandra Horning biography

Dr. Sandra Horning M.D. serves as Independent Director of the Company. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., until her retirement in 2019. During her 10-year career at Roche and Genentech, she helped bring 15 new medicines to patients in disease areas including cancer, multiple sclerosis, influenza and blindness. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to 2006, she served as President of the American Society of Clinical Oncology. Dr. Horning was recognized as the 2020 Healthcare Businesswomen’s Association Woman of the Year. She was also selected as the 2017 recipient of the Duane Roth Memorial Award, an honor dedicated to leaders in healthcare, whose work has overcome numerous scientific obstacles to create new paradigms in research and treatment. From 2015 to 2018, Dr. Horning served on the board of directors of Foundation Medicine. She currently serves as an advisor to EQRx.



How old is Sandra Horning?

Sandra Horning is 71, he's been the Independent Director of Gilead Sciences since 2020. There are 2 older and 23 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.

What's Sandra Horning's mailing address?

Sandra's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DR, REDWOOD CITY, CA, 94063.

Insiders trading at Gilead Sciences

Over the last 22 years, insiders at Gilead Sciences have traded over 221,090,692$ worth of Gilead Sciences stock and bought 30,121 units worth 1,879,767$ . The most active insiders traders include John C MartinNorbert W BischofbergerJohn F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of 3,341,365$. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth 51,721$.



What does Gilead Sciences do?

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.



What does Gilead Sciences's logo look like?

Gilead Sciences, Inc. logo

Complete history of Sandra Horning stock trades at Gilead Sciences、Moderna Inc、Revolution Medicines Inc、Olema Pharmaceuticals

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
28 Apr 2023 Sandra Horning
ディレクター
オプション行使 670 132.89$ 89,036$
28 Apr 2023
1,373
28 Apr 2022 Sandra Horning
ディレクター
オプション行使 703 142.52$ 100,192$
28 Apr 2022
703
3 May 2022 Sandra Horning
ディレクター
オプション行使 1,112 60.33$ 67,087$
3 May 2022
1,744
28 Jan 2021 Sandra Horning
ディレクター
オプション行使 632 64.68$ 40,878$
28 Jan 2021
632


Gilead Sciences executives and stock owners

Gilead Sciences executives and other stock owners filed with the SEC include: